MDNA55 - Revision history

Lazy at 08:21, 18 January 2025

2025-01-18T08:21:35Z

← Older revision		Revision as of 01:21, 18 January 2025
Line 13:		Line 13:
	\|toxicity_level=2.5		\|toxicity_level=2.5
	\|toxicity_explanation=The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.		\|toxicity_explanation=The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.
	}}		\|overview=MDNA55 is an investigational treatment for recurrent malignant gliomas that combines IL-4 and Pseudomonas exotoxin A, targeting tumor cells with high IL-4R expression. Early-phase trials have shown promising efficacy, with a 56% response rate and a 20% complete response rate, though it remains unapproved by the FDA and its side effects are still under evaluation.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:32:49Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:32, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.		\|notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.
	\|~~category~~=Antibody-Drug Conjugates and other protein-drug conjugates		\|treatment_category=Antibody-Drug Conjugates and other protein-drug conjugates
	\|links=		\|links=
	\|toxicity_level=2.5		\|toxicity_level=2.5
	\|toxicity_explanation=The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.		\|toxicity_explanation=The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.
	}}		}}

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:28Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 11:		Line 11:
	\|category=Antibody-Drug Conjugates and other protein-drug conjugates		\|category=Antibody-Drug Conjugates and other protein-drug conjugates
	\|links=		\|links=
			\|toxicity_level=2.5
			\|toxicity_explanation=The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=MDNA55 |FDA_approval=No |used_for=Recurrent malignant gliomas |clinical_trial_phase=Early phase trials |common_side_effects=Not specified in the provided text |OS_with=Not specified in the provided text |PFS_with=Not specified in the provided text |usefulness_rating=3 |notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56..."

2024-03-24T12:53:18Z

Created page with "{{TreatmentInfo |drug_name=MDNA55 |FDA_approval=No |used_for=Recurrent malignant gliomas |clinical_trial_phase=Early phase trials |common_side_effects=Not specified in the provided text |OS_with=Not specified in the provided text |PFS_with=Not specified in the provided text |usefulness_rating=3 |notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56..."

New page

{{TreatmentInfo
|drug_name=MDNA55
|FDA_approval=No
|used_for=Recurrent malignant gliomas
|clinical_trial_phase=Early phase trials
|common_side_effects=Not specified in the provided text
|OS_with=Not specified in the provided text
|PFS_with=Not specified in the provided text
|usefulness_rating=3
|notes=MDNA55, a fusion of IL-4 and Pseudomonas exotoxin A, targets cells with high IL-4R expression, common in tumor tissue. Preliminary data shows significant efficacy with a 56% response rate and a 20% complete response rate in recurrent glioblastoma patients treated with a single infusion, highlighting potential as a highly effective treatment.
|category=Antibody-Drug Conjugates and other protein-drug conjugates
|links=
}}